Shanghai Pioneer Holding Ltd (SH PIONEER HLDG) reported audited results for the year ended 31 December 2025 showing softer top- and bottom-line performance after the cessation of its Alcon ophthalmic distribution agreement.
Revenue and Profitability • Revenue fell 16.2% year on year to RMB1.28 billion, as sales from the Alcon co-promotion segment plunged 78.8% to RMB61.55 million following termination of the supply deal in August 2024. • Group gross profit slipped 8.2% to RMB627.14 million, but the consolidated gross margin improved to 48.9% (2024: 44.6%) on a more profitable sales mix. • Net profit attributable to shareholders declined 27.7% to RMB105.09 million; net margin narrowed to 8.2% (2024: 9.5%). • Basic and diluted EPS decreased 23.1% to RMB0.10.
Segment Performance • Comprehensive marketing, promotion and channel management services remained the core contributor, generating RMB1.22 billion in revenue (95.2% of total). – Pharmaceutical products revenue eased 3.1% to RMB431.02 million with margin rising to 70.0%. – Medical devices revenue slipped 0.6% to RMB790.86 million; margin contracted to 40.7%. • Revenue from ophthalmic products under the lapsed Alcon channel management fell sharply to RMB61.55 million, contributing just 4.8% of total sales versus 18.9% a year earlier.
Cost Structure and Expenses • Cost of sales declined 22.6% to RMB656.28 million, reflecting reduced Alcon volumes. • Distribution and selling expenses decreased 3.8% to RMB349.39 million but rose to 27.2% of revenue (2024: 23.7%). • Administrative expenses were up 2.8% to RMB137.59 million, equal to 10.7% of revenue (2024: 8.7%). • Other income dropped 66.5% to RMB14.99 million due mainly to lower government grants.
Cash Flow and Balance Sheet • Net operating cash inflow stood at RMB209.33 million (2024: RMB214.83 million). • Cash and cash equivalents rose to RMB166.61 million (31 Dec 2024: RMB103.57 million). • Net current assets totalled RMB672.78 million; the gearing ratio increased to 7.7% (31 Dec 2024: 4.3%) as bank borrowings grew to RMB114.60 million.
Dividend The Board proposes a final dividend of HKD0.054 per share (approximately RMB0.048), totalling about RMB60.36 million, subject to shareholder approval at the AGM scheduled for 22 May 2026. Together with the interim payout of HKD0.064 per share, total dividends for 2025 amount to approximately RMB127.47 million.
Operational Highlights • First repackaging line for Difene capsules at the Rongchang Production Base commenced operations, having passed both China GMP and EU-GMP audits. • Clinical trials for the Archimedes biodegradable biliary and pancreatic stent, acquired from Q3 Medical, began in April 2025. • Investments include stakes in DMAX Co. (25% shareholding) and two pharma-focused funds (Shanghai Yuhan and Jiaxing Yuhan), which contributed fair-value gains of RMB21.0 million in 2025.
Outlook Management notes ongoing industry restructuring from volume-based procurement, heightened compliance demands and enhanced market access for imported innovative therapies. Strategic priorities include expanding the product pipeline, optimising the nationwide marketing network and pursuing targeted M&A to solidify the Group’s position across the pharmaceutical supply chain.